Drug intelligence / Profile preview

ANS02

Development stage: Phase 2
Lead developer: Avistone Biotechnology
Modality: Small Molecules

Overview

ANS02 is a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being developed by Avistone Pharmaceutical. As a small molecule, it is specifically designed to overcome resistance mutations that arise following treatment with earlier generations of EGFR TKIs, such as the C797S mutation which often confers resistance to third-generation inhibitors like osimertinib. ANS02 is currently in the preclinical stage of development for the treatment of solid tumors, particularly non-small cell lung cancer (NSCLC) harboring specific EGFR mutations.

Other names: 4th-generation EGFR-TKI

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on ANS02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANS02.

Explore the full profile